<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG，Biologics Innovation Group是由致力于从事生物医药领域研究、开发、应用、临床、投资等工作的独立个人，自愿组织的一个专业/非盈利性机构。正式成立于2014年，迄今会员490余人，相继举办20余场行业峰会。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 10 Mar 2021 11:45:40 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>Roche等开发SAR-T：2+1双抗作为活性和安全开关</title><link>https://mp.weixin.qq.com/s/Mwxbwj_ozsoSai3D_i83Ig</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQOJtfv3ic8m4IVtYVgdeRnUH3TrM0nic8XViakuNaKGgMxfChePXQAdPd21zkQJ3Q4JKRSIIX6ImmxQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>活性可逆，安全有效的细胞治疗技术。]]></content:encoded><pubDate>Tue, 09 Mar 2021 22:43:39 +0800</pubDate></item><item><title>新药上市后商业化有多难？</title><link>https://mp.weixin.qq.com/s/hha7mG2b1al13CN3txBCfw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/GXvD9Cgfl9GfmLxOia29wiaTIjPxRxT8Dicc47ZO8JCwSoXVz8ibsZFXDbVbQicenEZrBTV8vJ0vAVoKuTwibqW4UicrQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>半数未达销售预期]]></content:encoded><pubDate>Tue, 09 Mar 2021 22:43:39 +0800</pubDate></item><item><title>百奥赛图CD40抗体申报临床，后PD-1时代新君之争愈加激烈</title><link>https://mp.weixin.qq.com/s/f-sI4TJEun5KUiFhx5eTAw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwSSJx8sHIINg7I5hDGqqJDyEesviahM5nc4sAByLtcV92YUcXAqffWRPy3J8WbYU28ObDqD0ibaiaViaA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>国内外CD40抗体在研项目有哪些？]]></content:encoded><pubDate>Mon, 08 Mar 2021 17:11:03 +0800</pubDate></item><item><title>折戟路上的勇士！如何通过临床策略提升ADC成功率？</title><link>https://mp.weixin.qq.com/s/-wibTYu2ciHsWeoP7kE3TQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS4fkUicNOM5owvrmozRtp0HHMj1fPF4iahZxibYb4EHEnFTSpibSyGW9nt1JTlZDXzqpZWWWz0ceDzHQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>九死一生的新药临床失败从来不是罕事]]></content:encoded><pubDate>Fri, 05 Mar 2021 21:35:00 +0800</pubDate></item><item><title>Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期</title><link>https://mp.weixin.qq.com/s/-mgaAjHM-rWwM3yhBv6ZOw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwSba4uJia16GhWuxkkCgVVRtp0tqGSGzPic746ianeNyFSe6rzad8SwoJh6GpdQeBTcZibVYhhfrmooIQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>2021年“全球十大突破性技术”名单，mRNA疫苗名列榜首。]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:26:43 +0800</pubDate></item><item><title>免疫单药真的落寞了么，双抗市场究竟蓝海多大？</title><link>https://mp.weixin.qq.com/s/HUjzyzoM77IcpUomM9LIZA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQeibj9MjkPorTwxJmx3iaSw0kesBvsDPRezd0SMX8wybs1MvmddyRrvWgTqytXQcRnYbFp9b1ibTjdw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>一文梳理双抗格局]]></content:encoded><pubDate>Wed, 03 Mar 2021 17:04:13 +0800</pubDate></item><item><title>缺氧耐药新解法！贝伐珠单抗难治性GBM 2期达到主要终点</title><link>https://mp.weixin.qq.com/s/lWm4o7yj24kobzPJksNxSQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS1HXkebqgt82f0b4ZTy9ylFjEqibf7ZzFr5HXVneINSZxk3oMZmhJWL7IicwdbzMN5kACKmaOOduVQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>有潜力的胶质母细胞瘤新药]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>信达生物新冠抗体项目美国FDA IND获批，苏桥助力2000L GMP生产</title><link>https://mp.weixin.qq.com/s/xTCYtnj4N4VgnqPafbGZYA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwS1HXkebqgt82f0b4ZTy9yljicI2Oa5epKiaUwxbj5h1iaNyEOSian7PhuLrKYkk7IAz9nuLlB02NO0gg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>]]></content:encoded><pubDate>Mon, 01 Mar 2021 17:12:48 +0800</pubDate></item><item><title>百花齐放！常见双特异性抗体技术平台</title><link>https://mp.weixin.qq.com/s/nPIdl0-0FASlqh_LYXoAhA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQbo0fBJiaPHrNYhTBxFXEXvHR7VH7ia0tjdbGFO8C1tb2qsPmaR2uibcjTCK8cDaBzxhTwTPUEAcdXQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>双抗目前有超过200种format]]></content:encoded><pubDate>Sat, 27 Feb 2021 22:22:03 +0800</pubDate></item><item><title>4-1BB+T细胞：免疫治疗革命的主角</title><link>https://mp.weixin.qq.com/s/D4pDhkRvytBPW3rH0NFBhw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQtylGWANJwicfOPm3KqJTicILicvIiaynuRzfLwNibGnQiaC6JUFjaBLfNqSeanSUInqrH9RKOWWvY0S7g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>4-1BB的潜力]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>新江湖｜医普科诺加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/mFMUuGfa3Xmx5TbjLtmHMw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwQtylGWANJwicfOPm3KqJTicImibHVzrPrmY9FkMvXfhLRCYPK5DKSdbTKtzBCgKlM6jTFGOkGxJjmjg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Scientific Driven, Making Impact.]]></content:encoded><pubDate>Fri, 26 Feb 2021 17:56:16 +0800</pubDate></item><item><title>双特异性纳米抗体，激活1型NKT细胞</title><link>https://mp.weixin.qq.com/s/vYG2X0q93FPymhsDu0aIeQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwT1loQIFAUhfGSNWY9oSOhBYKAl13FVQiaWibc24xxiaFK9diajD1vo0ibuicEfTeEQADNEzTP2tlWJtUug/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>NKT细胞越来越受关注。]]></content:encoded><pubDate>Tue, 23 Feb 2021 15:17:59 +0800</pubDate></item><item><title>抗Galectin-9与GITR激动剂的协同抗肿瘤作用</title><link>https://mp.weixin.qq.com/s/9sntacAt2lvp0GOAotOmwg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/m6gqgND1GwT1loQIFAUhfGSNWY9oSOhBQcyrGYZD7ialYBtdybDmpmhiaUpX0Jd8N1pibXkXXGiaLXBzUXJt6expog/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>Gal-9，一个非常有希望的免疫治疗靶点]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:03:52 +0800</pubDate></item></channel></rss>